Rogelio de J. Treviño-Rangel

Prof. Rogelio de J. Treviño-Rangel

Facultad de Medicina, Universidad Autónoma de Nuevo León., Monterrey, Nuevo León, Mexico
orcid
Head of Departamento de Microbiología-UANL

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
JBJacob Bodilsen
Jacob Bodilsen
QDQuintino Giorgio D'Alessandris
Quintino Giorgio D'Alessandris
HHHilary Humphreys
Hilary Humphreys
MIMildred A. Iro
Mildred A. Iro
MKMatthias Klein
Matthias Klein
MBMatthijs C. Brouwer
Matthijs C. Brouwer
These ESCMID guidelines are intended for clinicians involved in diagnosis and treatment of brain abscess in children and adults. Key questions were developed, and a systematic review was carried out of all studies published since January 1st, 1996, using the search terms "brain abscess" OR "cerebral abscess" as Mesh terms or text in electronic databases of PubMed, Embase, and the Cochrane registry. The search was updated on September 29th, 2022. Exclusion criteria were a sample size <10 patients or publication in non-English language. Extracted data was summarized as narrative reviews and tables. Metanalysis was carried out using a random effects model and heterogeneity was examined by I2 tests as well as funnel and Galbraith plots. Risk of bias was assessed using ROBINS-I (observational studies) and QUADAS-2 (diagnostic studies). The GRADE approach was applied to classify strength of recommendations (strong or conditional) and quality of evidence (high, moderate, low, or very low). MRI is recommended for diagnosis of brain abscess (strong, high). Antimicrobials may be withheld until aspiration or excision of brain abscess in patients without severe disease if neurosurgery can be carried out within reasonable time, preferably within 24 hours (conditional, low). Molecular-based diagnostics are recommended, if available, in patients with negative cultures (conditional, moderate). Aspiration or excision of brain abscess is recommended whenever feasible, except for cases with toxoplasmosis (strong, low). Recommended empirical antimicrobial treatment for community-acquired brain abscess in immuno-competent individuals is a 3rd generation cephalosporin and metronidazole (strong, moderate) with the addition of trimethoprim-sulfamethoxazole and voriconazole in patients with severe immuno-compromise (conditional, low). Recommended empirical treatment of post-neurosurgical brain abscess is a carbapenem combined with vancomycin or linezolid (conditional, low). The recommended duration of antimicrobial treatment is 6-8 weeks (conditional, low). No recommendation is offered for early transition to oral antimicrobials due to a lack of data, and oral consolidation treatment after ≥6 weeks of intravenous antimicrobials is not routinely recommended (conditional, very low). Adjunctive glucocorticoid treatment is recommended for treatment of severe symptoms due to perifocal oedema or impending herniation (strong, low). Primary prophylaxis with antiepileptics is not recommended (conditional, very low). Research needs are addressed.

1 May 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
HVHiram Villanueva-Lozano
Hiram Villanueva-Lozano
Rogelio de J. Treviño-RangelRogelio de J. Treviño-Rangel
Rogelio de J. Treviño-Rangel
GGGloria M. González
Gloria M. González
MRMaría Teresa Ramírez-Elizondo
María Teresa Ramírez-Elizondo
RLReynaldo Lara-Medrano
Reynaldo Lara-Medrano
MMMichel F. Martínez-Reséndez
Michel F. Martínez-Reséndez

24 December 2015 in Medical Mycology
Verified
Journal Article
Closed access
PDF file
Rogelio de J. Treviño-RangelRogelio de J. Treviño-Rangel
Rogelio de J. Treviño-Rangel
HVHiram Villanueva-Lozano
Hiram Villanueva-Lozano
PHPedro Hernández-Rodríguez
Pedro Hernández-Rodríguez
MMMichel F. Martínez-Reséndez
Michel F. Martínez-Reséndez
JGJaime Garcia-Juarez
Jaime Garcia-Juarez
GGGloria M. González
Gloria M. González
Cryptococcus neoformans infection is an important cause of meningitis in HIV/AIDS endemic regions. Antifungals for its management include amphotericin B, flucytosine, and fluconazole. Recently, treatment of this mycosis with sertraline has been studied with variable clinical outcomes. The aim of the study was to assess the in vitro antifungal effect of sertraline against clinical isolates of Cryptococcus spp. as well as its in vivo activity in a murine model of cryptococcal meningoencephalitis. The in vitro susceptibility to fluconazole, amphotericin B, voriconazole and sertraline of 153 Cryptococcus spp. strains were evaluated according to CLSI procedures. Fungal tissue burden, serum antigenaemia and histopathology, together with the therapeutic efficacy of amphotericin B (3 mg/kg), fluconazole (15 mg/kg), and sertraline (3, 10, and 15 mg/kg) were evaluated in mice intracranially inoculated with one isolate of Cryptococcus neoformans. All strains were susceptible to the antifungals studied and exhibited growth inhibition with sertraline at clinically relevant concentrations. Sertraline at a dose of 15 mg/kg reduced the fungal burden in the brain and spleen with an efficacy comparable to that of fluconazole. In conclusion, sertraline exhibited an excellent in vitro-in vivo anti-cryptococcal activity, representing a possible new alternative for the clinical management of meningeal cryptococcosis.

1 April 2013 in Medical Mycology
Verified
Journal Article
Closed access
Rogelio de J. Treviño-RangelRogelio de J. Treviño-Rangel
Rogelio de J. Treviño-Rangel
JGJ. Gerardo González
J. Gerardo González
GGGloria M. González
Gloria M. González
Candida parapsilosis is considered as an important emerging fungal pathogen and was recently found to be a complex that include three species, i.e., Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. The aim of this study was to determine the in vitro aspartyl proteinase, phospholipase, esterase and hemolysin activities of 65 clinical isolates of the C. parapsilosis complex, which had been previously identified by RFLP-BanI analysis. Of the enzymes evaluated, aspartyl proteinase was the least produced by the C. parapsilosis species complex. Phospholipase and esterase were strongly expressed by C. orthopsilosis (67% of isolates), while 10% and 13% of C. parapsilosis sensu stricto isolates were strong producers, respectively, of these two enzymes. In contrast, high production of both enzymes was not detected in C. metapsilosis. Hemolysin activity was significantly more abundant in C. orthopsilosis (87%) than C. parapsilosis sensu stricto (67%). Overall, C. orthopsilosis isolates were statistically associated with the production of hemolysins (P= 0.048) and phospholipases (P< 0.0001) compared to isolates of C. parapsilosis sensu stricto or C. metapsilosis. Furthermore, a statistical association was found between isolates recovered from blood and phospholipase production (P= 0.017). The distribution of isolates obtained from blood was 30% of C. parapsilosis sensu stricto, 67% of C. orthopsilosis and 20% of C. metapsilosis.

18 July 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
GGGloria M. González
Gloria M. González
Rogelio de J. Treviño-RangelRogelio de J. Treviño-Rangel
Rogelio de J. Treviño-Rangel
JPJosé P. Palma-Nicolás
José P. Palma-Nicolás
CLCesar Adrian Martinez Longoria
Cesar Adrian Martinez Longoria
JGJ. Gerardo González
J. Gerardo González
ABAlexandro Bonifaz
Alexandro Bonifaz
To establish the species distribution and in vitro susceptibilities of 358 bloodstream fungal isolates from paediatric patients in Mexico. Isolates were collected during a 2 year surveillance programme in 14 medical centres in 10 Mexican states. A molecular approach was used to determine the Candida parapsilosis species complex. In vitro susceptibility to amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, anidulafungin and micafungin was determined according to CLSI procedures. Species-specific clinical breakpoints for fluconazole, voriconazole and echinocandins were applied. Candida spp. accounted for 98.33% of fungaemias, including 127 Candida albicans isolates, 127 C. parapsilosis complex isolates (121 C. parapsilosis sensu stricto, 4 Candida orthopsilosis and 2 Candida metapsilosis strains) and 72 Candida tropicalis isolates. C. albicans and C. parapsilosis complex were the species predominant in neonates (48 cases each; 41.02%). C. parapsilosis complex was also the predominant species in patients 1 month to <2 years of age (P = 0.007). In contrast, C. albicans was the most frequent species in patients aged 2 to <12 years (P = 0.003). Antifungal resistance was rare among the subset of isolates. Candida glabrata showed the highest resistance rate to amphotericin B (1/9 isolates), fluconazole (1/9 isolates) and itraconazole (2/9 isolates). The species distribution differed with the age of the patients, with C. albicans and C. parapsilosis complex being the most commonly isolated species. C. glabrata showed the highest resistance rate to amphotericin B, fluconazole and itraconazole. This is the first study of fungaemia episodes in Mexican children.

28 October 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Rogelio de J. Treviño-RangelRogelio de J. Treviño-Rangel
Rogelio de J. Treviño-Rangel
GGGloria M. González
Gloria M. González
AMAlexandra M. Montoya
Alexandra M. Montoya
OCOlga Carolina
Olga Carolina
MEMariana Elizondo-Zertuche
Mariana Elizondo-Zertuche
NÁNeri Alejandro Álvarez-Villalobos
Neri Alejandro Álvarez-Villalobos
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals. These promising agents are currently in different stages of development, offering novel dosing regimens and mechanisms of action. A systematic search in MEDLINE, EMBASE, Web of Science, and Scopus up to 27 June 2022 was conducted to find relevant articles reporting data of in vitro activity and in vivo efficacy of investigational antifungals against C. auris. These included new additions to existing antifungal classes (rezafungin and opelconazole), first-in-class drugs such as ibrexafungerp, manogepix/fosmanogepix, olorofim and tetrazoles (quilseconazole, oteseconazole and VT-1598), as well as other innovative agents like ATI-2307, MGCD290 and VL-2397. From 592 articles retrieved in the primary search, 27 met the eligibility criteria. The most studied agent was manogepix/fosmanogepix (overall MIC90: 0.03 mg/L), followed by ibrexafungerp (overall MIC90: 1 mg/L) and rezafungin (overall MIC mode: 0.25 mg/L), while VT-1598 and ATI-2307 were the least explored drugs against C. auris. All these compounds demonstrated significant improvements in survival and reduction in tissue fungal burden on neutropenic animal models of candidemia due to C. auris. Continual efforts towards the discovery of new treatments against this multidrug-resistant fungus are essential.